Clinical Operations

Exec. Director of Strategy Paul Johnson discusses biomarker-driven approaches for complex pulmonary trials.

PharPoint’s Exec. Dir. of Strategy Paul Johnson discusses the use of enrichment strategies in complex pulmonary trials.

PharPoint’s Exec. Dir. of Strategy Paul Johnson discusses the use of adaptive trial design for complex pulmonary trials.

A look at a decade of Phase 1-4 studies in Japan and Taiwan, from 2015 to 2025 according to ClinicalTrial.Gov.

Learn what goes into an effective site feasibility questionnaire and how an experienced consultant can help inform your strategy.

Thorough planning is especially critical for Phase 1 trials, as even minor delays can cause major downstream effects.

What early tactics should you consider to improve your chances of a successful rare disease trial?

What should sponsors take into consideration when planning a schizophrenia clinical trial & download PharPoint’s experience overview.

Asking the right questions is key to determining how successful sites will be in ensuring the overall success of your Phase 1 study.

In this article , we discuss how CRAs review adverse events, including the role of a CRA and what documentation is needed.